Robert B. Kargbo, Ph.D.
Affiliations: | 2008 | North Dakota State University, Fargo, ND, United States |
Area:
Allylation, Medicinal ChemistryGoogle:
"Robert Kargbo"Mean distance: 8.51 | S | N | B | C | P |
Parents
Sign in to add mentor| Gregory R. Cook | grad student | 2008 | North Dakota State University | |
| (Asymmetric addition of organoindium reagent to hydrazones.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kargbo RB. (2020) RAF Kinases in Cancer: A Moving Target and Degradation Therapy. Acs Medicinal Chemistry Letters. 11: 1369-1370 |
| Kargbo RB. (2020) Chemically Induced Degradation of FAK-ALK for Application in Cancer Therapeutics. Acs Medicinal Chemistry Letters. 11: 1367-1368 |
| Kargbo RB. (2020) PROTAC Compounds Targeting Androgen Receptor for Cancer Therapeutics: Prostate Cancer and Kennedy's Disease. Acs Medicinal Chemistry Letters. 11: 1092-1093 |
| Kargbo RB. (2020) PROTAC Compounds Targeting TRK for Use in Cancer Therapeutics. Acs Medicinal Chemistry Letters. 11: 1090-1091 |
| Kargbo RB. (2020) Selective Estrogen Receptor Degraders for the Potential Treatment of Cancer. Acs Medicinal Chemistry Letters. 11: 412-413 |
| Kargbo RB. (2020) BRM Targeting Compounds for the Potential Treatment of Cancer. Acs Medicinal Chemistry Letters. 11: 99-100 |
| Kargbo RB. (2019) PROTAC Degradation of Bromodomain for the Treatment of Hyperplasia and Cancer. Acs Medicinal Chemistry Letters. 10: 1372-1373 |
| Kargbo RB. (2019) PROTAC Degradation of IRAK4 for the Treatment of Cancer. Acs Medicinal Chemistry Letters. 10: 1370-1371 |
| Kargbo RB. (2019) PROTAC-Mediated Degradation of Estrogen Receptor in the Treatment of Cancer. Acs Medicinal Chemistry Letters. 10: 1367-1369 |
| Kargbo RB. (2019) PROTACs and Targeted Protein Degradation for Treating ALK-Mediated Cancers. Acs Medicinal Chemistry Letters. 10: 1102-1103 |